Caris Life Sciences, Inc.(CAI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAI Caris Life Sciences, Inc.

交易中 06-12 12:21:03 EDT

17.93

-0.07

-0.39%

最高18.23	最低17.63	成交量80.43万
今开18.05	昨收18.00	日振幅3.33%
总市值50.59亿	流通市值16.48亿	总股本2.82亿
成交额1,448万	换手率0.88%	流通股本9,192万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAI","market":"US","secType":"STK","nameCN":"Caris Life Sciences, Inc.","latestPrice":17.93,"timestamp":1781281255670,"preClose":18,"halted":0,"volume":804289,"delay":0,"changeRate":-0.003888888888888905,"floatShares":91917486,"shares":282146923,"eps":-1.456,"marketStatus":"交易中","change":-0.07,"latestTime":"06-12 12:21:03 EDT","open":18.05,"high":18.23,"low":17.63,"amount":14477419.15803,"amplitude":0.033333,"askPrice":17.94,"askSize":142,"bidPrice":17.91,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.456,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781294400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1750219200000,"exchange":"NASDAQ","adjPreClose":18,"preHourTrading":{"tag":"盘前","latestPrice":18.1,"preClose":18,"latestTime":"09:29 EDT","volume":4881,"amount":88575.06770999999,"timestamp":1781270970116,"change":0.1,"changeRate":0.005556,"amplitude":0.020556},"postHourTrading":{"tag":"盘后","latestPrice":18.01,"preClose":18,"latestTime":"19:59 EDT","volume":119016,"amount":2147879.1884,"timestamp":1781222397825,"change":0.01,"changeRate":0.000556,"amplitude":0.055},"volumeRatio":0.62162,"impliedVol":0.5617,"impliedVolPercentile":0.065},"requestUrl":"/m/hq/s/CAI/tweets","defaultTab":"tweets","newsList":[{"id":"2641348011","title":"Caris Life Sciences授权1亿美元股票回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2641348011","media":"环球市场播报","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641348011?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:35","pubTimestamp":1780929300,"startTime":"0","endTime":"0","summary":"精准医疗公司Caris Life Sciences6月8日宣布，其董事会已授权一项最高达1亿美元的普通股回购计划。Caris计划以现有现金及现金等价物为此次回购提供资金支持。根据公司此前发布的第一季度财报，Caris在2026年第一季度实现总营收2.162亿美元，同比增长79%，其中分子分析服务收入增长85%至2.108亿美元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-08/doc-iniathze8537387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","CAI","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101513685","title":"Caris Life Sciences 计划以可用现金及现金等价物为股票回购计划提供资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1101513685","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101513685?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:33","pubTimestamp":1780921985,"startTime":"0","endTime":"0","summary":"Caris Life Sciences 公司表示，其股票回购计划预计将完全通过现有的现金及现金等价物提供资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122496389","title":"Caris生命科学向纽约州卫生部提交Caris Assure血液检测授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1122496389","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122496389?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:08","pubTimestamp":1778270891,"startTime":"0","endTime":"0","summary":"Caris生命科学公司已正式向纽约州卫生部递交申请，旨在为其Caris Assure血液检测技术获取授权许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118576658","title":"Caris生命科学公司Caris Chromoseq获Moldx批准，推动髓系恶性肿瘤全面基因组图谱检测可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1118576658","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118576658?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:32","pubTimestamp":1777897936,"startTime":"0","endTime":"0","summary":"Caris生命科学公司宣布，其Caris Chromoseq检测技术已获得Moldx认证批准。这一重要进展将显著提升髓系恶性肿瘤患者获取全面基因组图谱检测服务的便利性。\n该项认证标志着Caris公司在精准医疗领域迈出关键一步。通过Moldx的权威认可，医疗机构和患者能够更便捷地运用这项先进技术，为髓系恶性肿瘤的精准诊断和治疗方案制定提供有力支持。\nCaris Chromoseq技术的推广应用，将助力临床医生基于个体基因特征制定个性化治疗方案，最终改善髓系恶性肿瘤患者的治疗效果和生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160274437","title":"财报前瞻｜Caris Life Sciences, Inc.本季度营收预计同比持平，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1160274437","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160274437?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:05","pubTimestamp":1777539947,"startTime":"0","endTime":"0","summary":"Caris Life Sciences, Inc.将于2026年05月07日盘后发布财报，市场预期本季度营收约2.10亿美元、调整后每股收益约-0.02美元。市场一致预期显示，Caris Life Sciences, Inc.本季度营收预计为2.10亿美元，调整后每股收益预计为-0.02美元；公司层面未给出本季度毛利率与净利润或净利率的量化指引，相关预测数据暂无。公司近期在检测项目上持续扩充：推出用于预测高级别浆液性卵巢癌对铂类化疗耐受风险的AI工具，嵌入Caris AI Insights平台，为临床医生提供风险评分与敏感性预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Caris Life Sciences, Inc.本季度营收预计同比持平，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628273004","title":"华安保险：李云焕因个人原因辞去公司总经理职务 指定CAI ZHENGYUAN为临时负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2628273004","media":"金融一线","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628273004?lang=zh_cn&edition=full","pubTime":"2026-04-17 15:16","pubTimestamp":1776410160,"startTime":"0","endTime":"0","summary":"4月17日金融一线消息，华安财产保险股份有限公司近日公告称，李云焕因个人原因辞去公司总经理职务，根据公司第九届董事会第十次临时会议决议，董事会指定 CAI ZHENGYUAN先生为公司临时负责人，指定期不超过六个月。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王馨茹","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/2026-04-17/doc-inhuutza2283707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CAI","BK4104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146321171","title":"Caris生命科学公司与Blue Owl Capital及黑石集团达成新信贷协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1146321171","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146321171?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:30","pubTimestamp":1775161821,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Caris生命科学公司（Caris Life Sciences, Inc.）已与Blue Owl Capital及黑石集团（Blackstone）正式签署了一项新的信贷协议。\n该协议的达成标志着Caris生命科学公司在资本结构优化方面迈出关键一步，为其未来的研发投入与业务扩张提供了坚实的资金支持。此次合作也凸显了Blue Owl Capital与黑石集团对生命科学领域创新企业的持续看好。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","CAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149391494","title":"Caris生命科学公司信贷协议披露：4亿美元定期贷款、3亿美元延迟提款及5亿美元增量融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1149391494","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149391494?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:30","pubTimestamp":1775161820,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会（SEC）文件，Caris生命科学公司（Caris Life Sciences Inc）已达成一项综合性信贷协议。该协议包含三部分核心融资安排：一项4亿美元的定期贷款、一项3亿美元的延迟提款贷款，以及一项高达5亿美元的增量融资额度。\n此项信贷安排显著增强了公司的财务灵活性。定期贷款提供即时资金支持，延迟提款机制允许公司根据未来需求分阶段获取资金，而增量融资额度则为潜在的战略扩张预留了充足空间。\n这一融资动作为Caris生命科学后续的研发投入与业务拓展提供了坚实的资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAI","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613257766","title":"Caris Life Sciences, Inc.盘中异动 早盘大幅下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613257766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613257766?lang=zh_cn&edition=full","pubTime":"2026-02-24 00:15","pubTimestamp":1771863331,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日00时15分，Caris Life Sciences, Inc.股票出现波动，股价快速下跌5.02%。Caris Life Sciences, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Arcellx, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Vanda Pharmaceuticals Inc.涨幅较大，Psyence Biomedical Ltd.、Genprex, Inc.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为214.45%、174.53%、119.86%，振幅较大的相关个股有Abpro Holdings Inc C/Wts 12/11/2029 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Biovie Inc C/Wts 08/08/2030，振幅分别为70.43%、66.80%、36.63%。Caris Life Sciences, Inc.公司简介：Caris Life Sciences Inc是一家以患者为中心的下一代人工智能技术生物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602240015319541b058&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602240015319541b058&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAI","BK4104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150846900","title":"财报前瞻 ｜Caris Life Sciences, Inc.本季度营收预计增0.00%，机构观点看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1150846900","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150846900?lang=zh_cn&edition=full","pubTime":"2026-02-19 12:11","pubTimestamp":1771474280,"startTime":"0","endTime":"0","summary":"Caris Life Sciences, Inc.将于2026年02月26日美股盘后发布最新季度财报，市场关注营收动能与盈利质量的延续性。市场一致预期本季度公司营收约为2.39亿USD，同比0.00%；调整后每股收益约为0.03USD，同比0.00%；息税前利润约为2,267.41万USD，同比0.00%；当前未见对毛利率与净利率的明确预测及同比数据，故不展示。该季度息税前利润为3,264.20万USD，较市场预估显著改善，超预期金额5,274.91万USD，超预期幅度达262.34%，同步带动每股收益表现优于预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Caris Life Sciences, Inc.本季度营收预计增0.00%，机构观点看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607570240","title":"Caris Life Sciences, Inc.盘中异动 大幅下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607570240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607570240?lang=zh_cn&edition=full","pubTime":"2026-01-30 00:45","pubTimestamp":1769705122,"startTime":"0","endTime":"0","summary":"北京时间2026年01月30日00时45分，Caris Life Sciences, Inc.股票出现波动，股价快速下跌5.00%。Caris Life Sciences, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Briacell Therapeutics Corp C/Wts 、Serina Therapeutics, Inc.、Sangamo Therapeutics, Inc.涨幅较大，Serina Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.、Gri Bio, Inc.较为活跃，换手率分别为568.42%、111.61%、76.80%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Biomx Inc.、Aprea Therapeutics, Inc.，振幅分别为104.32%、38.75%、27.75%。Caris Life Sciences, Inc.公司简介：Caris Life Sciences Inc是一家以患者为中心的下一代人工智能技术生物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130004523a6bc82dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130004523a6bc82dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4104","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111919288","title":"Caris生命科学真实世界数据揭示转移性乳腺癌患者对德曲妥珠单抗的应答与耐药机制","url":"https://stock-news.laohu8.com/highlight/detail?id=1111919288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111919288?lang=zh_cn&edition=full","pubTime":"2026-01-28 21:34","pubTimestamp":1769607255,"startTime":"0","endTime":"0","summary":"Caris生命科学最新发布的真实世界临床数据，揭示了转移性乳腺癌患者在接受德曲妥珠单抗（Trastuzumab Deruxtecan）治疗过程中的药物应答模式及耐药性发展轨迹。这项研究通过对真实诊疗环境中患者数据的深度挖掘，为这一靶向疗法的临床效果提供了更贴近实际应用的观察视角。研究结果不仅勾勒出患者群体的差异化反应图谱，同时为后续治疗方案优化及耐药机制破解提供了关键线索。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602592136","title":"Binance Alpha 现已上线 CharacterX(CAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602592136","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602592136?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:03","pubTimestamp":1768204998,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方页面显示，Binance Alpha 已上线 CharacterX(CAI)。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2236616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","CAI.AU","BK4139","BK4104","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602599317","title":"币安 Alpha 将上线 CharacterX (CAI)，空投门槛为 252 个 Alpha 积分","url":"https://stock-news.laohu8.com/highlight/detail?id=2602599317","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602599317?lang=zh_cn&edition=full","pubTime":"2026-01-12 14:57","pubTimestamp":1768201043,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，币安 Alpha 将上线 CharacterX (CAI) ，Alpha 交易将于 2026 年 1 月 12 日 16:00（UTC+8）开始。\n\n持有至少 252 个币安 Alpha 积分的用户可申领代币空投。在 Alpha 活动页面申领 40 个 CAI 代币空投，先到先得。若活动未结束，则分数门槛将每五分钟自动降低 5 分。\n\n请注意，申领空投将消耗 15 个币安 Alpha 积分。用户需在 Alpha 活动页面 24 小时内确认申领，否则视为放弃领取空投。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2236594","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","CAI.AU","BK7104","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602595795","title":"Binance Alpha新项目CAI空投门槛为252个积分","url":"https://stock-news.laohu8.com/highlight/detail?id=2602595795","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602595795?lang=zh_cn&edition=full","pubTime":"2026-01-12 06:23","pubTimestamp":1768170180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//flash/327733","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_zh_live","symbols":["BK4104","CAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602155166","title":"MEXC Meme+ 交易区即将上线 CAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2602155166","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602155166?lang=zh_cn&edition=full","pubTime":"2026-01-11 21:55","pubTimestamp":1768139731,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，根据官方消息，MEXC Meme+ 交易区将于 2026 年 1 月 12 日 18:00 (UTC+8)上线 CAI，1 月 13 日 18:00 (UTC+8)开通提币服务。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2236439","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAI","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602899385","title":"币安 Alpha 将于 1 月 12 日上线 CharacterX(CAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602899385","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602899385?lang=zh_cn&edition=full","pubTime":"2026-01-10 13:02","pubTimestamp":1768021320,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方消息，币安 Alpha 将于 1 月 12 日上线 CharacterX (CAI)。一旦交易开放，符合条件的用户可以在 Alpha 活动页面使用币安 Alpha Points 领取空投。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2236264","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK7104","BK4139","CAI","CAI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595728648","title":"CAI控股(00080)：戴文轩辞任公司财务总监","url":"https://stock-news.laohu8.com/highlight/detail?id=2595728648","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595728648?lang=zh_cn&edition=full","pubTime":"2025-12-31 12:33","pubTimestamp":1767155624,"startTime":"0","endTime":"0","summary":"智通财经APP讯，CAI控股(00080)公布，戴文轩先生已辞任公司财务总监，以发展其他事业，其最后受雇日期为2025年12月31日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1511","CAI","BK4139","00080","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593100129","title":"石药新诺威董事CAI LEI（蔡磊）因工作变动辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2593100129","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593100129?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:27","pubTimestamp":1766392022,"startTime":"0","endTime":"0","summary":"中访网数据 石药创新制药股份有限公司于2025年12月22日发布公告，公司董事会收到董事CAI LEI(蔡磊)先生的书面辞职报告。CAI LEI(蔡磊)先生因工作变动原因，申请辞去公司董事职务，辞任后不再担任公司任何职务。其辞职报告自送达董事会之日起生效。公告显示，CAI LEI(蔡磊)先生原定任期至2026年4月6日届满，此次辞任未导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251222/31881169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4139","BK4104","LU2039709279.SGD","IE00B5MMRT66.SGD","BK0226","LU0314109678.HKD","LU1152091754.HKD","LU1960683339.HKD","BK1515","BK1521","LU1226287875.USD","LU1226288253.USD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU1813983027.USD","LU0140636845.USD","LU0072913022.USD","LU0315179316.USD","LU1993786604.SGD","SG9999004220.SGD","LU1807302812.USD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1226288170.HKD","01093","BK1191","LU1226287529.USD","LU1328277881.USD","HK0000165453.HKD","LU1226287792.SGD","LU1951186391.HKD","IE00BZ08YR35.GBP","300765","LU0501845795.SGD","LU0326950275.SGD","LU0067412154.USD","CAI","LU0880133367.SGD","IE0008368742.USD","LU1152091168.USD","LU1008478684.HKD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592975819","title":"CAI控股(00080.HK)：建议采纳2025年股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2592975819","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592975819?lang=zh_cn&edition=full","pubTime":"2025-12-17 20:17","pubTimestamp":1765973824,"startTime":"0","endTime":"0","summary":"格隆汇12月17日丨CAI控股(00080.HK)公告，公司于2015年5月28日采纳之2015年购股权计划已于2025年5月31日届满。2015年购股权计划届满后，不可进一步提呈或授出购股权。于本公告日期，并无2015年购股权计划项下尚未行使之购股权。\r\n\r\n　　鉴于2015年购股权计划之届满，董事会建议根据上市规则第17章采纳2025年股份计划，以为合资格参与者对本公司增长及发展所作出或将会作出之贡献向彼等提供激励或奖赏。2025年股份计划之条款将载于将寄发予股东之通函内。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251217/31872595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["00080","BK4139","BK4104","CAI","BK1511"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carislifesciences.com","stockEarnings":[{"period":"1week","weight":0.0417},{"period":"1month","weight":0.074},{"period":"3month","weight":-0.0083},{"period":"6month","weight":-0.3274},{"period":"1year","weight":-0.1429},{"period":"ytd","weight":-0.3328}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Caris Life Sciences, Inc.于2011年11月根据开曼群岛法律注册成立，并于2020年7月在德克萨斯州重新注册成立，总部位于德克萨斯州欧文。他们是一家领先的、以患者为中心的下一代AI科技生物公司和精准医疗先驱。他们开发并商业化创新解决方案，通过大规模使用综合分子信息和人工智能/机器学习算法来改变医疗保健。他们的整个精准医疗解决方案组合旨在造福患者，最初的重点是肿瘤学，并服务于临床、学术和生物制药市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":0.003709},{"month":2,"riseRate":0.714286,"avgChangeRate":0.097096},{"month":3,"riseRate":0.785714,"avgChangeRate":0.045627},{"month":4,"riseRate":0.642857,"avgChangeRate":0.069907},{"month":5,"riseRate":0.571429,"avgChangeRate":0.009049},{"month":6,"riseRate":0.4,"avgChangeRate":0.003897},{"month":7,"riseRate":0.533333,"avgChangeRate":0.001503},{"month":8,"riseRate":0.466667,"avgChangeRate":0.000804},{"month":9,"riseRate":0.533333,"avgChangeRate":-0.003567},{"month":10,"riseRate":0.666667,"avgChangeRate":0.042552},{"month":11,"riseRate":0.533333,"avgChangeRate":0.007248},{"month":12,"riseRate":0.4,"avgChangeRate":-0.027079}],"exchange":"NASDAQ","name":"Caris Life Sciences, Inc.","nameEN":"Caris Life Sciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Caris Life Sciences, Inc.(CAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Caris Life Sciences, Inc.(CAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Caris Life Sciences, Inc.,CAI,Caris Life Sciences, Inc.股票,Caris Life Sciences, Inc.股票老虎,Caris Life Sciences, Inc.股票老虎国际,Caris Life Sciences, Inc.行情,Caris Life Sciences, Inc.股票行情,Caris Life Sciences, Inc.股价,Caris Life Sciences, Inc.股市,Caris Life Sciences, Inc.股票价格,Caris Life Sciences, Inc.股票交易,Caris Life Sciences, Inc.股票购买,Caris Life Sciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Caris Life Sciences, Inc.(CAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Caris Life Sciences, Inc.(CAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}